Clinical Trial Update: Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports safety and dose information for GRN163L in patients with refractory or relapsed multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• GRN163L (imetelstat)

Snippet

Sponsor: Geron Corporation | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED